Kainova Therapeutics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7171 Frederick Banting, Montreal, Quebec...Website
www.kainovatx.comRevenue
$9.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Kainova Therapeutics
Kainova Therapeutics is a clinical stage biopharmaceutical company developing GPCR modulating therapies in immuno oncology and inflammation. Its teams in Canada and Europe advance small molecule and antibody programs to reshape tumor and immune responses for patients with limited options.Explore more
Kainova Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kainova Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Kainova Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Kainova Therapeutics has new funding data
Earning: See what the market has to say on Kainova Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Kainova Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Kainova Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Kainova Therapeutics launches new products
Kainova Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Kainova Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Kainova Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Kainova Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kainova Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kainova Therapeutics.
Kainova Therapeutics financials insights
Gather financial insights about Kainova Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series B
$23.6M
Kainova Therapeutics News & Media
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.Kainova closes $32 million to advance cancer and inflammation therapies
New backer Investissement Québec led the first close of the biopharma firm’s Series B round. The post Kainova closes $32 million to advance cancer and inflammation therapies first appeared on BetaKit.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Kainova Therapeutics
Sign Up For FreeTo access detailed company insights
Kainova Therapeutics is a clinical stage biopharmaceutical company developing GPCR modulating therapies in immuno oncology and inflammation. Its teams in Canada and Europe advance small molecule and antibody programs to reshape tumor and immune responses for patients with limited options.... Read More
